The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Patient-centric quality standards are a key component of ensuring patient access to safe and efficacious cell and gene therapies. Two case studies relevant to ex vivo autologous T cell therapeutics will be presented, together highlighting how the identification of product-relevant attributes and understanding of clinical exposure range can factor into product specification setting.